AdFAST does not induce fusion or promote survival in immunodeficient CD-1 mice with subcutaneous A549 tumors.

Abstract

<p><b>A)</b> CD-1 nude mice harbouring subcutaneous A549 tumors were intratumorally injected with PBS, 5x10⁸ pfu AdEmpty or AdFAST. Five days post injection, tumors were excised, fixed, sectioned and subjected to hematoxylin and eosin staining. Results are representative of 2–3 mice (10x objective). <b>B)</b> CD-1 mice with subcutaneous A549 tumors intratumorally injected with PBS, 5x10⁸ pfu AdEmpty or AdFAST were measured at day 20 post injection. The line in each column represents the average of the associated treatment group. <b>C)</b> A Kaplan-Meier survival curve shows the percentage survival of CD-1 mice with subcutaneous A549 tumors intratumorally injected with PBS, AdEmpty or AdFAST over time. Each treatment group consisted of 5 mice.</p